408 related articles for article (PubMed ID: 32339655)
1. Do Lewy bodies contain alpha-synuclein fibrils? and Does it matter? A brief history and critical analysis of recent reports.
Lashuel HA
Neurobiol Dis; 2020 Jul; 141():104876. PubMed ID: 32339655
[TBL] [Abstract][Full Text] [Related]
2. Lewy body-associated proteins: victims, instigators, or innocent bystanders? The case of AIMP2 and alpha-synuclein.
Lashuel HA; Novello S
Neurobiol Dis; 2021 Aug; 156():105417. PubMed ID: 34102275
[TBL] [Abstract][Full Text] [Related]
3. The subcellular arrangement of alpha-synuclein proteoforms in the Parkinson's disease brain as revealed by multicolor STED microscopy.
Moors TE; Maat CA; Niedieker D; Mona D; Petersen D; Timmermans-Huisman E; Kole J; El-Mashtoly SF; Spycher L; Zago W; Barbour R; Mundigl O; Kaluza K; Huber S; Hug MN; Kremer T; Ritter M; Dziadek S; Geurts JJG; Gerwert K; Britschgi M; van de Berg WDJ
Acta Neuropathol; 2021 Sep; 142(3):423-448. PubMed ID: 34115198
[TBL] [Abstract][Full Text] [Related]
4. Endogenous oligodendroglial alpha-synuclein and TPPP/p25α orchestrate alpha-synuclein pathology in experimental multiple system atrophy models.
Mavroeidi P; Arvanitaki F; Karakitsou AK; Vetsi M; Kloukina I; Zweckstetter M; Giller K; Becker S; Sorrentino ZA; Giasson BI; Jensen PH; Stefanis L; Xilouri M
Acta Neuropathol; 2019 Sep; 138(3):415-441. PubMed ID: 31011860
[TBL] [Abstract][Full Text] [Related]
5. Stereotaxic Targeting of Alpha-Synuclein Pathology in Mouse Brain Using Preformed Fibrils.
Zhang B; Kehm V; Gathagan R; Leight SN; Trojanowski JQ; Lee VM; Luk KC
Methods Mol Biol; 2019; 1948():45-57. PubMed ID: 30771169
[TBL] [Abstract][Full Text] [Related]
6. Prominent astrocytic alpha-synuclein pathology with unique post-translational modification signatures unveiled across Lewy body disorders.
Altay MF; Liu AKL; Holton JL; Parkkinen L; Lashuel HA
Acta Neuropathol Commun; 2022 Nov; 10(1):163. PubMed ID: 36371251
[TBL] [Abstract][Full Text] [Related]
7. Trans-synaptic and retrograde axonal spread of Lewy pathology following pre-formed fibril injection in an in vivo A53T alpha-synuclein mouse model of synucleinopathy.
Schaser AJ; Stackhouse TL; Weston LJ; Kerstein PC; Osterberg VR; López CS; Dickson DW; Luk KC; Meshul CK; Woltjer RL; Unni VK
Acta Neuropathol Commun; 2020 Aug; 8(1):150. PubMed ID: 32859276
[TBL] [Abstract][Full Text] [Related]
8. α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.
Henderson MX; Trojanowski JQ; Lee VM
Neurosci Lett; 2019 Sep; 709():134316. PubMed ID: 31170426
[TBL] [Abstract][Full Text] [Related]
9. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation.
Lázaro DF; Rodrigues EF; Langohr R; Shahpasandzadeh H; Ribeiro T; Guerreiro P; Gerhardt E; Kröhnert K; Klucken J; Pereira MD; Popova B; Kruse N; Mollenhauer B; Rizzoli SO; Braus GH; Danzer KM; Outeiro TF
PLoS Genet; 2014 Nov; 10(11):e1004741. PubMed ID: 25393002
[TBL] [Abstract][Full Text] [Related]
10. Propagation of pathological α-synuclein in marmoset brain.
Shimozawa A; Ono M; Takahara D; Tarutani A; Imura S; Masuda-Suzukake M; Higuchi M; Yanai K; Hisanaga SI; Hasegawa M
Acta Neuropathol Commun; 2017 Feb; 5(1):12. PubMed ID: 28148299
[TBL] [Abstract][Full Text] [Related]
11. Neuropathology and molecular diagnosis of Synucleinopathies.
Koga S; Sekiya H; Kondru N; Ross OA; Dickson DW
Mol Neurodegener; 2021 Dec; 16(1):83. PubMed ID: 34922583
[TBL] [Abstract][Full Text] [Related]
12. Defining a Lewy Body: Running Up the Hill of Shifting Definitions and Evolving Concepts.
Moors TE; Milovanovic D
J Parkinsons Dis; 2024; 14(1):17-33. PubMed ID: 38189713
[TBL] [Abstract][Full Text] [Related]
13. Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes.
Chu Y; Muller S; Tavares A; Barret O; Alagille D; Seibyl J; Tamagnan G; Marek K; Luk KC; Trojanowski JQ; Lee VMY; Kordower JH
Brain; 2019 Nov; 142(11):3565-3579. PubMed ID: 31580415
[TBL] [Abstract][Full Text] [Related]
14. ⍺-Synuclein Structural Diversity and the Cellular Environment in ⍺-Synuclein Transmission Models and Humans.
Peelaerts W; Baekelandt V
Neurotherapeutics; 2023 Jan; 20(1):67-82. PubMed ID: 37052776
[TBL] [Abstract][Full Text] [Related]
15. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
[TBL] [Abstract][Full Text] [Related]
16. Can the lack of fibrillar form of alpha-synuclein in Lewy bodies be explained by its catalytic activity?
Kuznetsov IA; Kuznetsov AV
Math Biosci; 2022 Feb; 344():108754. PubMed ID: 34890628
[TBL] [Abstract][Full Text] [Related]
17. A NAC domain mutation (E83Q) unlocks the pathogenicity of human alpha-synuclein and recapitulates its pathological diversity.
Kumar ST; Mahul-Mellier AL; Hegde RN; Rivière G; Moons R; Ibáñez de Opakua A; Magalhães P; Rostami I; Donzelli S; Sobott F; Zweckstetter M; Lashuel HA
Sci Adv; 2022 Apr; 8(17):eabn0044. PubMed ID: 35486726
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of alpha-synuclein toxicity: An update and outlook.
Brás IC; Xylaki M; Outeiro TF
Prog Brain Res; 2020; 252():91-129. PubMed ID: 32247376
[TBL] [Abstract][Full Text] [Related]
19. Nuclear alpha-synuclein is present in the human brain and is modified in dementia with Lewy bodies.
Koss DJ; Erskine D; Porter A; Palmoski P; Menon H; Todd OGJ; Leite M; Attems J; Outeiro TF
Acta Neuropathol Commun; 2022 Jul; 10(1):98. PubMed ID: 35794636
[TBL] [Abstract][Full Text] [Related]
20. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration.
Mahul-Mellier AL; Burtscher J; Maharjan N; Weerens L; Croisier M; Kuttler F; Leleu M; Knott GW; Lashuel HA
Proc Natl Acad Sci U S A; 2020 Mar; 117(9):4971-4982. PubMed ID: 32075919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
